Sehn LH, et al. - In patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), researchers estimated overall survival (OS) benefit correlated with polatuzumab vedotin (pola) + bendamustine (B) + rituximab (R) vs BR alone. They used data from a Ph2 randomised controlled trial of pola-BR compared to BR in patients with R/R DLBCL. According to findings, estimated mean OS (assuming a Weibull distribution) was between 1.9 yrs (parametric model) and 4.7 yrs (mixture model) for pola-BR, vs 0.8 yrs for BR (both models). Sensitivity analysis exhibited that censoring (at time of initiation) patients receiving stem-cell transplant/chimeric antigen receptor T-cell therapy had no impact on the estimates, implying the impacts were because of pola-BR and not subsequent therapy. These models indicate that pola-BR is linked to a 4-year increase in life-years and at least a fourfold increase in the proportion of long-term survivors vs BR alone.